Mirabegron
Active pharmaceutical substance formulated in Jan Aushadhi generic products for Kidney & Urinary Care treatment.
🧴 Clinical Application
Take orally once daily, 25 mg to 50 mg with water, with or without food. Swallow the extended-release tablet whole; do NOT crush, divide, or chew. In severe renal impairment (eGFR 15-29 mL/min) or moderate hepatic impairment (Child-Pugh B), do not exceed 25 mg daily.
⚠️ Side Effects
Common: Hypertension (elevated blood pressure), urinary tract infection, headache, nasopharyngitis, tachycardia. Rare/Severe: Severe hypertensive crisis (BP >= 180/110 mmHg), urinary retention (especially in bladder outlet obstruction), and angioedema.
🛡️ Safety Warnings
Regularly monitor blood pressure before initiating and periodically during therapy; strictly contraindicated in severe uncontrolled hypertension (systolic BP >= 180 mmHg and/or diastolic BP >= 110 mmHg). Moderate inhibitor of CYP2D6; increases plasma levels of metoprolol, desipramine, and flecainide.
Jan Aushadhi Products containing Mirabegron
Found 2 generic formulation(s) containing this active ingredient.
Mirabegron Extended-release Tablets 25 mg
Mirabegron Extended-Release Tablets (25mg, 50mg) is a first-in-class, potent and selective beta-3 adrenergic receptor agonist on the WHO Model List framework for Overactive Bladder (OAB). In the urinary bladder, it stimulates beta-3 adrenergic receptors on the detrusor muscle during the urine storage phase, activating adenylyl cyclase and raising cyclic AMP, relaxing detrusor muscle tone and increasing bladder storage capacity without anticholinergic dry mouth, constipation, or cognitive impairment. Indicated for symptomatic treatment of urgency, increased micturition frequency, and urgency incontinence associated with Overactive Bladder.
Mirabegron Extended-release Tablets 50 mg
Mirabegron Extended-Release Tablets (25mg, 50mg) is a first-in-class, potent and selective beta-3 adrenergic receptor agonist on the WHO Model List framework for Overactive Bladder (OAB). In the urinary bladder, it stimulates beta-3 adrenergic receptors on the detrusor muscle during the urine storage phase, activating adenylyl cyclase and raising cyclic AMP, relaxing detrusor muscle tone and increasing bladder storage capacity without anticholinergic dry mouth, constipation, or cognitive impairment. Indicated for symptomatic treatment of urgency, increased micturition frequency, and urgency incontinence associated with Overactive Bladder.
Brand Equivalents & Price Comparison
Compare Jan Aushadhi generic prices against popular commercial brands for Mirabegron.
| Generic Formulation | Pack Size | Jan Aushadhi Price | Commercial Brand Equivalents | Avg. Commercial Price | Savings |
|---|---|---|---|---|---|
| Mirabegron Extended-release Tablets 25 mg | 10's | ₹93.75 | MIRAGO, MIRBEG, MIRABIG, URIHOLD, BLADMIR | ₹270.47 | 65% Save |
| Mirabegron Extended-release Tablets 50 mg | 10's | ₹135.94 | MIRAGO, MIRBEG, MIRABIG, MIRAGRON, MEGATAS | ₹397.57 | 66% Save |
Frequently Asked Questions (FAQ)
Get answers to common queries about Mirabegron generics.